The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
The Landscape of Targeted Therapies in TNBC
Open accessAbstract
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months. Chemotherapy is the mainstay of treatment while there is a growing body of evidence that targeted therapies may be on the horizon with poly-ADP-ribose polymerase (PARP) and immune check-point inhibitors already established in the treatment paradigm of TNBC. A large number of novel therapeutic agents are being evaluated for their efficacy in TNBC. As novel therapeutics are now incorporated into clinical practice, it is clear that tumor heterogeneity and clonal evolution can result to de novo or acquired treatment resistance. As precision medicine and next generation sequencing is part of cancer diagnostics, tailored treatment approaches based on the expression of molecular markers are currently being implemented in clinical practice and clinical trial design. The scope of this review is to highlight the most relevant current knowledge regarding underlying molecular profile of TNBC and its potential application in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · cited 1×
“Compared to basal-like TN, LAR tumors are associated with lower grade, occur in postmenopausal women of older age, and have low pCR rate when treated with neoadjuvant chemotherapy [12].”
BackgroundAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · cited 1×
“Individuals who inherit mutations in BRCA genes are at higher risk of developing not only BC, but also high-grade serous ovarian carcinoma (HGSOC), pancreatic, gastric, and other solid tumors [21].”
BackgroundThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“In hormone HR positive disease everolimus, an m-TOR inhibitor, is being used to overcome resistance to endocrine treatment and PI3k inhibitor alpelisib, showed activity in hormone resistant, PIK3CA mutated tumors [97,98].”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · cited 1×
“Alterations on the genes encoding for the above proteins lead to HR repair deficiency (HRD) and increased risk of cancer [26].”
BackgroundAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“In TNBC, PIK3CA is the second most frequently detected mutation after TP53, yet the implication of PI3K/AKT/mTOR inhibitors in this subset of BC is not well defined [99].”
BackgroundGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“Further investigation in the future might identify the most effective combinations or the subgroup of patients most likely to respond to mTOR inhibitors [45,100].”
BackgroundPereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226 · cited 1×
“Upon activation, poly ADP-ribosylation (PARylation) is catalytic for the recruitment of downstream DNA repair effectors such as DNA ligase III, DNA polymerase β, topoisomerases and XRCC1 and the chromatin structure remodeling [34].”
BackgroundHomologous recombination in DNA repair and DNA damage tolerance
Li, X., & Heyer, W.-D. (2008) · Cell Research · doi:10.1038/cr.2008.1 · Cited by 1,197
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim, C., Gao, R., Sei, E., Brandt, R., Hartman, J., Hatschek, T., Crosetto, N., Foukakis, T., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2018.03.041 · Cited by 1,104
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · cited 1×
“The median overall survival for metastatic patients is approximately eighteen months, much lower compared to the HR positive and HER2 enriched disease where survival may exceed five years [6].”
BackgroundPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Ha, H., Debnath, B., & Neamati, N. (2017) · Theranostics · doi:10.7150/thno.15625 · Cited by 789
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779 · cited 1×
“This fact classifies it among the most potent and cytotoxic PARPi [69].”
BackgroundLoibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
El-Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 659
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 604
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Kreienberg, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111065 · Cited by 530
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
Exploring and comparing adverse events between PARP inhibitors
LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30786-1 · Cited by 487
Domchek, S. M., Postel-Vinay, S., Im, S.-A., Park, Y. H., Delord, J.-P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30324-7 · Cited by 484
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130142 · Cited by 447
Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., & Silvestris, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918794630 · Cited by 423
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Integrated Profiling of Basal and Luminal Breast Cancers
Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2536 · Cited by 297
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy460 · Cited by 295
Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., Jakubowicz, J., Cybulski, C., Wisniowski, R., Godlewski, D., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3100-x · Cited by 269
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Hopkins, T. A., Ainsworth, W. B., Ellis, P. A., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Abraham, V. C., Algire, M. A., Shi, Y., Olson, A. M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0138 · Cited by 250
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Schott, A. F., Goldstein, L. J., Cristofanilli, M., Ruffini, P. A., McCanna, S., Reuben, J. M., Perez, R. P., Kato, G., & Wicha, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2748 · Cited by 238
Self-citationLips, E. H., Mulder, L., Oonk, A., van der Kolk, L. E., Hogervorst, F. B. L., Imholz, A. L. T., Wesseling, J., Rodenhuis, S., & Nederlof, P. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.144 · Cited by 231
Singh, J. K., Farnie, G., Bundred, N. J., Simões, B. M., Shergill, A., Landberg, G., Howell, S. J., & Clarke, R. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1063 · Cited by 217
Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
Ruffini, E., Asioli, S., Filosso, P. L., Lyberis, P., Bruna, M. C., Macrì, L., Daniele, L., & Oliaro, A. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.10.067 · Cited by 205
Nanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero-Torres, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204
Transcriptional Roles of PARP1 in Cancer
Schiewer, M. J., & Knudsen, K. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0672 · Cited by 186
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Siegel, M. B., He, X., Hoadley, K. A., Hoyle, A., Pearce, J. B., Garrett, A. L., Kumar, S., Moylan, V. J., Brady, C. M., Van Swearingen, A. E. D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96153 · Cited by 183
Antibody-Drug Conjugates: Possibilities and Challenges.
Nejadmoghaddam, M.-R., Minai‐Tehrani, A., Ghahremanzadeh, R., Mahmoudi, M., Dinarvand, R., & Zarnani, A. (2019) · Europe PMC (PubMed Central) · Cited by 182
Martín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
Beyond DNA repair, the immunological role of PARP ‐1 and its siblings
Rosado, M. M., Bennici, E., Novelli, F., & Pioli, C. (2013) · Immunology · doi:10.1111/imm.12099 · Cited by 178
Lianidou, E., & Pantel, K. (2019) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22695 · Cited by 171
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 167
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 164
Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., Gianni, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1003 · Cited by 164
Zaragoza, J., Caille, A., Bénéton, N., Bens, G., Christiann, F., Maillard, H., & Machet, L. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14155 · Cited by 156
Jovanović, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., Kuba, M. G., Estrada, M. V., Beeler, J. S., Shaver, T. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3055 · Cited by 156
Huang, J., Wang, L., Cong, Z., Amoozgar, Z., Kiner, E., Xing, D., Oršulić, S., Matulonis, U. A., & Goldberg, M. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.083 · Cited by 153
Alba, E., Chacón, J. I., Lluch, A. M., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Seguí, M. Á., Ribelles, N., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2100-y · Cited by 147
DNA breaks and chromosomal aberrations arise when replication meets base excision repair
Ensminger, M., Iloff, L., Ebel, C., Nikolova, T., Kaina, B., & Löbrich, M. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201312078 · Cited by 141
von Minckwitz, G., Loibl, S., Untch, M., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu455 · Cited by 139
Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2876-z · Cited by 133
Musolino, A., Bella, M., Bortesi, B., Michiara, M., Naldi, N., Zanelli, P., Capelletti, M., Pezzuolo, D., Camisa, R., Savi, M., et al. (2007) · Breast · doi:10.1016/j.breast.2006.12.003 · Cited by 132
Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
Wang, C., Pan, B., Zhu, H., Zhou, Y., Mao, F., Lin, Y., Xu, Q., & Sun, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10208 · Cited by 132
Iwata, H., Im, S., Masuda, N., Im, Y., Inoue, K., Rai, Y., Nakamura, R., Kim, J. H., Hoffman, J., Zhang, K., et al. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.008318 · Cited by 130
DNA repair in cancer initiation, progression, and therapy—a double-edged sword
Kiwerska, K., & Szyfter, K. (2019) · Journal of Applied Genetics · doi:10.1007/s13353-019-00516-9 · Cited by 121
Targeted therapy for triple‐negative breast cancer: Where are we?
Duffy, M. J., McGowan, P. M., & Crown, J. P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27632 · Cited by 116
Gonzalez-Angulo, A. M., Akçakanat, A., Liu, S., Green, M. C., Murray, J. L., Chen, H., Palla, S. L., Koenig, K. B., Brewster, A. M., Valero, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu124 · Cited by 110
Overexpression of DNA repair genes is associated with metastasis: A new hypothesis
Sarasin, A. R., & Kauffmann, A. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2007.12.002 · Cited by 101
Zhang, P., Yin, Y., Mo, H., Zhang, B., Wang, X., Li, Q., Yuan, P., Wang, J., Zheng, S., Cai, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10607 · Cited by 91
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
Evans, D. G., Howell, A., Ward, D., Lalloo, F. I., Jones, J. L., & Eccles, D. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100006 · Cited by 87
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 85
Asano, Y., Kashiwagi, S., Onoda, N., Kurata, K., Morisaki, T., Noda, S., Takashima, T., Ohsawa, M., Kitagawa, S., & Hirakawa, K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.434 · Cited by 84
Pellegrino, B., Mateo, J., Serra, V., & Balmañà, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000480 · Cited by 74
Schmid, P., Adams, S., Rugo, H. S., Schneeweiß, A., Barrios, C. H., Iwata, H., Dieras, V. C., Henschel, V., Molinero, L. L., Chui, S. Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1003 · Cited by 71
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Dulaney, C. R., Marcrom, S., Stanley, J. A., & Yang, E. S.-H. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.01.007 · Cited by 70
A Key Role for Poly(ADP-Ribose) Polymerase-1 Activity during Human Dendritic Cell Maturation
Aldinucci, A., Gerlini, G., Fossati, S., Cipriani, G., Ballerini, C., Biagioli, T., Pimpinelli, N., Borgognoni, L., Massacesi, L., Moroni, F., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.305 · Cited by 66
Poggio, F. B., Bruzzone, M., Ceppi, M., Conte, B., Martel, S., Maurer, C., Tagliamento, M., Viglietti, G., Mastro, L. D., de Azambuja, E., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000361 · Cited by 66
Keegan, T. H. M., Kurian, A. W., Gali, K., Tao, L., Lichtensztajn, D. Y., Hershman, D. L., Habel, L. A., Caan, B. J., & Gomez, S. L. (2015) · RePEc: Research Papers in Economics · doi:10.2105/ajph.2014.302406_5 · Cited by 62
von Minckwitz, G., Hahnen, E., Fasching, P. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.1005 · Cited by 61
Bi, Y., Verginadis, I. I., Dey, S., Lin, L. L., Guo, L., Zheng, Y., & Koumenis, C. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.002 · Cited by 61
Biomarkers for Basal-like Breast Cancer
Choo, J. R., & Nielsen, T. O. (2010) · Cancers · doi:10.3390/cancers2021040 · Cited by 60
Hilborn, E., Gacic, J., Fornander, T., Nordenskjöld, B. A., Stål, O., & Jansson, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.464 · Cited by 53
Sikov, W. M., Polley, M. C., Twohy, E. L., Perou, C. M., Singh, B., Berry, D. A., Tolaney, S. M., Somlo, G., Port, E. R., Ma, C. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.591 · Cited by 52
Miller, K. D., Tong, Y., Jones, D. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1082 · Cited by 50
Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M. L., Kaufman, B., Robson, M. E., Telli, M. L., Dieras, V. C., Han, H. S., Garber, J. E., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0412 · Cited by 48
von Minckwitz, G., Kaufmann, M., Kümmel, S., Fasching, P. A., EIERMANN, W., Blohmer, J., Costa, S., Loibl, S., Dietmar, V., & Untch, M. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-79 · Cited by 37
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Laudisi, F., Sambucci, M., & Pioli, C. (2011) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153011797881184 · Cited by 37
Domchek, S. M., Postel-Vinay, S. C., Im, S., Park, Y. H., Delord, J., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-pd5-04 · Cited by 17
Grellety, T., MacGrogan, G. M., Chakiba, C., Kind, M., & Bonnefoi, H. R. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00223 · Cited by 9
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Ding, Y., Chen, X., Liu, C., Ge, W., Wang, Q., Hao, X., Wang, M., Chen, Y., & Zhang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01016-8 · Cited by 415
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Chen, Q., Zhang, M., Huang, H., Dong, C., Dai, X., Feng, G., Lin, L., Sun, D., Yang, D., Xie, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202206244 · Cited by 83
Zhang, H., Zhu, S., Zhou, H., Li, R., Xia, X., & Xiong, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098357 · Cited by 46
Metadata
- Authors
- Vagia, E., Mahalingam, D., & Cristofanilli, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-04-08
- Volume
- 12
- Issue
- 4
- Pages
- 916
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3015456794
- Cited by
- 450
- References
- 129
- FWCI
- 17.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.